Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10532381 | 1.00 | LMNA (0.57) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1044220 | 0.87 | LMNA (0.56) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8168821 | 0.86 | LMNA (0.55) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3727438 | 0.86 | LMNA (0.55) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14861579 | 0.85 | GLO1 (0.51) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2353731 | 0.85 | ALDH1A1 (0.53) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29866817 | 0.85 | LMNA (0.54) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9308387 | 0.84 | LMNA (0.54) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10531013 | 0.84 | LMNA (0.54) | LMNANPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4656875 | 0.84 | LMNA (0.54) | LMNANPSR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486491-B1 | CARBOXYLIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7351705-B2 | Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1486491-A1 | CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-4839379-A | AROMATASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | UACA, CPA3, HCAR1 | LMNA 4217/4885NPSR1 487/4885CYP3A4 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.